Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI.

J Clin Oncol. 2009 Aug 10;27(23):3794-801. doi: 10.1200/JCO.2008.18.7815. Epub 2009 Jun 29.

PMID:
19564535
2.

New therapeutic approaches to treat medullary thyroid carcinoma.

Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M.

Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):22-32. Review.

PMID:
18084343
3.

Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.

Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G.

Am J Kidney Dis. 2007 Aug;50(2):203-18. Review.

PMID:
17660022
4.

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA.

Cancer Res. 2007 Jul 15;67(14):6956-64.

5.

A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.

Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, Saijo N.

J Thorac Oncol. 2006 Nov;1(9):1002-9.

6.

Toxicities of antiangiogenic therapy in non-small-cell lung cancer.

Herbst RS.

Clin Lung Cancer. 2006 Dec;8 Suppl 1:S23-30. Review.

PMID:
17239287
8.

Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.

Santoro M, Carlomagno F.

Nat Clin Pract Endocrinol Metab. 2006 Jan;2(1):42-52. Review.

PMID:
16932252
9.

RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.

Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB.

Thyroid. 2005 Jun;15(6):531-44. Review.

PMID:
16029119
10.

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI.

Ann Oncol. 2005 Aug;16(8):1391-7. Epub 2005 May 19.

PMID:
15905307
12.

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M.

Cancer Res. 2002 Dec 15;62(24):7284-90.

13.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF.

Cancer Res. 2002 Aug 15;62(16):4645-55.

14.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.

PMID:
10655437
15.

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.

Bunone G, Vigneri P, Mariani L, Butó S, Collini P, Pilotti S, Pierotti MA, Bongarzone I.

Am J Pathol. 1999 Dec;155(6):1967-76.

16.

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr.

Hum Mol Genet. 1993 Jul;2(7):851-6.

PMID:
8103403
17.

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, et al.

Nature. 1993 Jun 3;363(6428):458-60.

PMID:
8099202
18.

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.

Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JW, van Amstel HK, Romeo G, et al.

Nature. 1994 Jan 27;367(6461):375-6.

PMID:
7906866

Supplemental Content

Support Center